In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

July 14, 2020

HCP Live

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

Read Full Article

Topics

Media Requests

Journalist or member of the media?
We are available 24/7 for media requests.

Media Contact

Keep Up With McLean

Back to top

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

HCP Live

Media Requests

You May Also Like

In the Media: Ketamine for Depression Could Help Relieve Some of the Mental Health Burden Caused by Pandemic, Experts Say

McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant

In the Media: McLean Hospital and GrayMatters Health Awarded a BIRD Foundation Grant to Develop a Digital Therapy for Major Depression Disorder With Anhedonia Symptoms

Keep Up With McLean

Follow Us